Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market- Regional Analysis
Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market- Regional Analysis
Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market- Cross Sectional Analysis:
Key players are making relapsed or refractory diffuse large B cell lymphoma with combination of drug which is expected to drive the relapsed or refractory diffuse large B cell lymphoma market in North America region. For instance, in April 2021, Eagle Pharmaceuticals, Inc., a pharmaceutical company with research and development, clinical, manufacturing and commercial expertise, announced that TREAKISYM ready-to-dilute (“RTD”) (bendamustine hydrochloride 120 mg/m2) liquid formulation had been approved for a new indication in combination with rituximab (“BR therapy”) as treatment for relapsed or refractory diffuse large B-cell lymphoma (“r/r DLBCL”) by the Pharmaceuticals and Medical Devices Agency (“PMDA”) in Japan.
Relapsed or Refractory Diffuse Large B-cell Lymphoma Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients